Lyphe Group

What Lyphe Group does

Lyphe Group (legally Lyphe Clinic Ltd) is a UK private medical cannabis clinic founded in 2019, operating as one of the earliest specialist entrants after the November 2018 legalisation of cannabis-based products for medicinal use. The company runs a digital-first, video-only telemedicine model serving patients across the UK and Channel Islands, with no physical clinic visits required. Its core product is an integrated patient journey: a structured eligibility checker (£9.99 fee credited to first consultation), specialist GMC-registered clinician video consultations (£49 per appointment), internal triage, multidisciplinary team (MDT) panel review, prescription issuance, and medication delivery through its wholly-owned affiliated pharmacy, Lyphe Dispensary Ltd. Clinical governance is anchored by a High Usage Guidance (HUG) Panel that reviews complex or high-dose prescribing cases, with additional compliance around UK GDPR, CQC-aligned standards, and pharmaceutical-grade sourcing from licensed producers in Canada, Australia, and Europe as well as domestic cultivation partner Gro-Vida.

The company monetises across six revenue streams: pay-as-you-go consultation fees (£49/appointment), recurring subscription plans (Lyphe Saver at £9.99/month or £99.99/year), per-prescription medication revenue routed through Lyphe Dispensary (£50–£300 per patient per month), a hardware/CBD e-commerce storefront (Lyphe Shop), a £25-credit referral programme (Friends for Lyphe), and a free-lifetime veterans access scheme that generates no direct revenue but anchors a specific patient vertical. The business serves four primary use-case segments — chronic pain and neurological patients (primary), psychiatric and mental health patients, women's health patients, and gastrointestinal/oncological patients — plus a dedicated UK Armed Forces veterans persona. Lyphe joined Tilray Brands in 2024, providing global supply chain scale, and operates as a subsidiary of the Eezy Group Limited conglomerate alongside the Travel Clinic Farnborough Ltd subsidiary.

Lyphe is a privately held company registered in England with no disclosed venture or growth equity funding rounds in the available data. Headcount is in the 11–50 range, consistent with a small specialist clinical team supplemented by remote specialist prescribers. The company has served thousands of patients cumulatively since 2019 and is actively scaling via product formulary expansion (including the Noidecs range in 2025), pricing/access improvements, and dedicated segment programmes such as the veterans scheme and free clinic transfers from competitors.

Name

Lyphe Group

Legal name

Lyphe Clinic Ltd

Website

https://lyphe.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Lyphe Group operates a digital-first UK medical cannabis clinic delivering specialist video consultations, prescriptions, and integrated medication fulfilment via its Lyphe Dispensary pharmacy to private patients across the UK and Channel Islands, with a Tilray Brands affiliation since 2024.

Ownership category

akta.pro rank

Product category

Medical Cannabis Clinic / Telemedicine Healthcare

NAICS

Offices of Physicians (except Mental Health Specialists) (621111), Offices of Physicians, Mental Health Specialists (621112)

SIC

Retail-Drug Stores And Proprietary Stores (5912), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industries

Prescription-Based Digital Clinics (Condition-Specific Rx Programs) (HLALAAAD), Cannabis Subscription & Membership Delivery Programs (CRANAGAI), Medical Cannabis Delivery & Online Ordering (CRANAGAG)

Keywords

• Medical cannabis clinic
• Telemedicine consultations
• Cannabis prescriptions
• Patient care services
• Specialist pharmacy

Headquarters

HQ city

Farnborough

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Revenue model

1. Consultation fees (pay-as-you-go): Patients pay per clinical appointment: £49 for initial consultation and follow-up appointments, £25 for repeat prescription appointments without medication changes. Appointments conducted via secure video call.
2. Subscription plan (Lyphe Saver): Monthly subscription at £9.99/month or annual subscription at £99.99/year. Subscription includes initial consultation, quarterly follow-ups, one free repeat prescription per month, free standard travel letters, free annual medication review, 10% discount at Lyphe Shop, and free shipping through Lyphe Dispensary. Generates predictable recurring revenue from approved patients.
3. Prescription medication revenue: Revenue from dispensing medical cannabis through Lyphe Dispensary. Medication costs are separate from consultation fees and range from £50 to £300 per month depending on condition and product. Lyphe Dispensary delivers medication directly to patients.
4. Lyphe Shop (vaping hardware and CBD products): E-commerce storefront selling vaping hardware devices, accessories, and CBD products to patients and consumers. Prices displayed in GBP inclusive of VAT where applicable.
5. Friends for Lyphe Referral Programme: Existing patients earn £25 Lyphe Credit per successful referral when a referred patient completes a consultation, is approved, and receives their first prescription from Lyphe Dispensary. Referrals incentivise patient-driven acquisition.
6. Lyphe for Veterans Access Scheme: Free lifetime membership covering consultation, subscription, and repeat prescription fees for eligible UK veterans. Generates goodwill and veteran patient volume without direct revenue from membership fees.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels10 records

Core offering

Lyphe Group operates a UK-based digital-first medical cannabis clinic that delivers specialist doctor consultations via secure video, prescriptions, and medication delivery through its affiliated Lyphe Dispensary pharmacy. Patients complete an online eligibility check, attend video appointments with GMC-registered specialist clinicians, receive prescriptions reviewed by an MDT panel, and have cannabis-based medicines dispatched directly to their homes. The clinic is supplemented by subscription plans (Lyphe Saver), a retail shop for vaping hardware/CBD products, and a Veterans Access Scheme.

Product overview

Lyphe Clinic operates as a digital-first medical cannabis clinic platform offering a unified patient journey from eligibility assessment through prescription delivery. The core offering combines Lyphe Clinic (specialist consultations and prescription management) with Lyphe Dispensary (partner pharmacy for medication fulfillment), supported by subscription plans (Lyphe Saver Monthly/Annual), the Lyphe Shop (vaping accessories and CBD products), and special programs including the Lyphe for Veterans Access Scheme and Friends for Lyphe referral programme.

Differentiator

Problem solved

Functional benefit

Products and services

• Lyphe Clinic UK specialist medical cannabis clinic offering online eligibility assessment, specialist video consultations with GMC-registered clinicians, MDT panel review, prescription issuance, and ongoing patient care for chronic conditions where conventional treatments have failed.
• Lyphe Dispensary Affiliated digital-first specialist pharmacy that dispenses and delivers medical cannabis prescriptions directly to patients' doors, offering free shipping for subscription patients.
• Lyphe Shop Online retail store offering vaping hardware devices, accessories, and CBD products to UK customers aged 18+.
• Lyphe for Veterans Access Scheme Free lifetime membership programme for eligible UK Armed Forces veterans providing coverage of consultation, subscription, and repeat prescription fees.
• Friends for Lyphe Referral Programme Patient referral programme paying £25 Lyphe Credit per successful referral; referred patients receive six months free subscription and complimentary Summary of Care Record handling.

Quantifiable outcome

• 81% cheaper than pay-as-you-go plan based on one year (Lyphe Saver Annual)
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Tilray Brands Inc.coreStrategic or Co-development PartnerLyphe Clinic joined Tilray Brands, a global cannabis company, as part of a strategic partnership. The affiliation brings together Lyphe's UK medical cannabis clinic operations with Tilray's global cannabis production and distribution capabilities, enhancing product access and supply chain reliability for UK patients.
• Gro-VidacoreStrategic or Co-development PartnerLyphe Clinic maintains a unique relationship with growing partner Gro-Vida to ensure consistent UK medical cannabis supply for patients. Gro-Vida is a cannabis cultivation partner providing reliable domestic production capacity that complements imported products.
• CancardminorGTM or Marketing PartnerLyphe Clinic collaborates with Cancard, a cannabis prescription card scheme that provides patients with identification documentation for interactions with law enforcement. The partnership builds community trust and supports patient advocacy by validating legitimate medical cannabis use.
• Licensed Producers (Canada, Australia, Europe)coreOthersMedical cannabis prescribed by Lyphe is sourced from licensed producers in Canada, Australia, and Europe (including Portugal). These producers operate under strict pharmaceutical standards and regulatory oversight in their respective countries, ensuring product quality and safety.
• NoidecsminorOthersLyphe expanded its product formulary to include a new range of Noidecs medical cannabis products, providing patients with more treatment options tailored to individual needs. The expanded formulary was announced as part of Lyphe's 2025 access and affordability improvements.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• CB1 Medical: Smaller UK medical cannabis clinic offering specialist consultations and prescriptions. Overlaps with Lyphe on indication coverage but at smaller scale, providing a relevant niche competitor benchmark.

Direct peers

• Leva Clinic: UK private medical cannabis clinic offering online specialist consultations, prescriptions, and pharmacy partnerships. Targets similar chronic pain, mental health, and women’s health indications as Lyphe.
• Zerenia Clinics: UK medical cannabis clinic launched by Khiron Life Sciences, providing specialist consultations and prescriptions via telemedicine. Comparable subscription and consultation-based revenue model.
• Mamedica: UK-based private medical cannabis clinic providing specialist consultations and prescriptions for chronic pain, psychiatric, and neurological conditions. Closely comparable D2C telemedicine model targeting similar patient demographics.
• Sapphire Medical Clinics: One of the largest UK private medical cannabis clinic groups, offering GMC-registered specialist consultations and prescriptions across chronic pain, psychiatry, and neurology. Directly comparable digital-first prescribing model with similar pricing and subscription mechanics.
• Alternaleaf: UK private medical cannabis clinic delivering specialist video consultations and prescriptions across chronic pain, anxiety, and sleep indications. Operates a similar D2C digital-first clinic model to Lyphe.
• Integro Medical Cannabis Clinic: UK specialist medical cannabis clinic with both online and in-person consultations, covering pain, psychiatry, neurology, and palliative care. Comparable patient cohorts and prescription-led revenue model.
• Curaleaf Clinic (UK): UK arm of Curaleaf International operating a specialist medical cannabis clinic with video consultations, repeat prescriptions, and pharmacy dispensing. Competes head-to-head with Lyphe across similar indications and patient segments.

Others

• Gro-Vida: UK-based medical cannabis cultivator partnered with Lyphe to ensure domestic supply. Adjacent ecosystem participant supplying product into Lyphe’s dispensary and reducing import dependence.

Broad incumbents

• Tilray Brands: Global cannabis leader that Lyphe joined in 2024. Operates a broad portfolio of medical cannabis brands, cultivation, and distribution worldwide; relevant as both parent/partner and as a broader incumbent shaping the UK medical cannabis supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/lypheclinic
• Facebookfacebook.com/lypheclinicuk

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyphe Group